Linked Life Data

2433333

Source:http://linkedlifedata.com/resource/pubmed/id/2433333

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2433333rdf:typepubmed:Citationlld:pubmed
pubmed-article:2433333lifeskim:mentionsumls-concept:C0035366lld:lifeskim
pubmed-article:2433333lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:2433333lifeskim:mentionsumls-concept:C0022688lld:lifeskim
pubmed-article:2433333lifeskim:mentionsumls-concept:C0205147lld:lifeskim
pubmed-article:2433333lifeskim:mentionsumls-concept:C0033684lld:lifeskim
pubmed-article:2433333lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:2433333lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:2433333lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:2433333lifeskim:mentionsumls-concept:C1334043lld:lifeskim
pubmed-article:2433333lifeskim:mentionsumls-concept:C0597551lld:lifeskim
pubmed-article:2433333pubmed:issue3lld:pubmed
pubmed-article:2433333pubmed:dateCreated1987-3-2lld:pubmed
pubmed-article:2433333pubmed:abstractTextIt has been shown previously that the retroviral envelope protein p15E suppresses certain monocyte and lymphocyte functions. In this paper, we describe the effects on natural killer (NK) activity of a synthetic peptide (CKS-17) with homology to a region of p15E conserved among numerous retroviruses. Enriched human NK cells were assayed against K562 tumor target cells in a 51Cr-release cytotoxicity assay. Pretreatment of NK cells with CKS-17 at concentrations as low as 1.5 microM, but not with equivalent concentrations of control materials, markedly and reproducibly suppressed NK lytic activity. Prior exposure of NK cells to interferon-alpha (IFN-alpha) at 1000 U/ml did not alter their sensitivity to CKS-17-induced inhibition. Pretreating NK cells with CKS-17 almost entirely diminished their responsiveness to IFN-alpha and IFN-gamma, but not to interleukin 2 (IL 2). Kinetics experiments demonstrated that CKS-17-mediated suppression of both endogenous and activated NK cells was reversible after 18 hr at 37 degrees C. Experiments designed to examine the CKS-17 mechanism of action revealed that the peptide bound to all Leu-11+ lymphocytes, as shown by two-color flow cytometry. CKS-17 did not, however, inhibit effector cell/target cell conjugate formation. These data suggest a new mechanism for immune suppression mediated by retroviruses; inhibition of NK function. They moreover imply that the CKS-17 peptide interferes with the lytic phase of NK cytolysis.lld:pubmed
pubmed-article:2433333pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2433333pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2433333pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2433333pubmed:languageenglld:pubmed
pubmed-article:2433333pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2433333pubmed:citationSubsetAIMlld:pubmed
pubmed-article:2433333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2433333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2433333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2433333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2433333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2433333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2433333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2433333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2433333pubmed:statusMEDLINElld:pubmed
pubmed-article:2433333pubmed:monthFeblld:pubmed
pubmed-article:2433333pubmed:issn0022-1767lld:pubmed
pubmed-article:2433333pubmed:authorpubmed-author:SnydermanRRlld:pubmed
pubmed-article:2433333pubmed:authorpubmed-author:CiancioloG...lld:pubmed
pubmed-article:2433333pubmed:authorpubmed-author:KorenH SHSlld:pubmed
pubmed-article:2433333pubmed:authorpubmed-author:ArgovSSlld:pubmed
pubmed-article:2433333pubmed:authorpubmed-author:HarrisD TDTlld:pubmed
pubmed-article:2433333pubmed:issnTypePrintlld:pubmed
pubmed-article:2433333pubmed:day1lld:pubmed
pubmed-article:2433333pubmed:volume138lld:pubmed
pubmed-article:2433333pubmed:ownerNLMlld:pubmed
pubmed-article:2433333pubmed:authorsCompleteYlld:pubmed
pubmed-article:2433333pubmed:pagination889-94lld:pubmed
pubmed-article:2433333pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:2433333pubmed:meshHeadingpubmed-meshheading:2433333-...lld:pubmed
pubmed-article:2433333pubmed:meshHeadingpubmed-meshheading:2433333-...lld:pubmed
pubmed-article:2433333pubmed:meshHeadingpubmed-meshheading:2433333-...lld:pubmed
pubmed-article:2433333pubmed:meshHeadingpubmed-meshheading:2433333-...lld:pubmed
pubmed-article:2433333pubmed:meshHeadingpubmed-meshheading:2433333-...lld:pubmed
pubmed-article:2433333pubmed:meshHeadingpubmed-meshheading:2433333-...lld:pubmed
pubmed-article:2433333pubmed:meshHeadingpubmed-meshheading:2433333-...lld:pubmed
pubmed-article:2433333pubmed:meshHeadingpubmed-meshheading:2433333-...lld:pubmed
pubmed-article:2433333pubmed:meshHeadingpubmed-meshheading:2433333-...lld:pubmed
pubmed-article:2433333pubmed:meshHeadingpubmed-meshheading:2433333-...lld:pubmed
pubmed-article:2433333pubmed:meshHeadingpubmed-meshheading:2433333-...lld:pubmed
pubmed-article:2433333pubmed:meshHeadingpubmed-meshheading:2433333-...lld:pubmed
pubmed-article:2433333pubmed:meshHeadingpubmed-meshheading:2433333-...lld:pubmed
pubmed-article:2433333pubmed:meshHeadingpubmed-meshheading:2433333-...lld:pubmed
pubmed-article:2433333pubmed:meshHeadingpubmed-meshheading:2433333-...lld:pubmed
pubmed-article:2433333pubmed:meshHeadingpubmed-meshheading:2433333-...lld:pubmed
pubmed-article:2433333pubmed:year1987lld:pubmed
pubmed-article:2433333pubmed:articleTitleInhibition of human natural killer cell activity by a synthetic peptide homologous to a conserved region in the retroviral protein, p15E.lld:pubmed
pubmed-article:2433333pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2433333pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2433333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2433333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2433333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2433333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2433333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2433333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2433333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2433333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2433333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2433333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2433333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2433333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2433333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2433333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2433333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2433333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2433333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2433333lld:pubmed